Vixotrigine
Clinical data | |
---|---|
Other names | Raxatrigine; CNV1014802; GSK-1014802; BIIB 074 |
Routes of administration | By mouth |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H19FN2O2 |
Molar mass | 314.360 g·mol−1 |
3D model (JSmol) | |
| |
|
Vixotrigine (INN , USAN ), formerly known as raxatrigine (INN , USAN ), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[citation needed] Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.[citation needed] As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]
See also
[edit]References
[edit]- ^ "CNV1014802". Convergence Pharmaceuticals.
- ^ McMahon S, Koltzenburg M, Tracey I, Turk DC (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
- ^ Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
- ^ a b "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG.
External links
[edit]